About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4819157
Allelic
Composition
Zfp36l1tm1.1Tnr/Zfp36l1tm1.1Tnr
Zfp36l2tm1.1Tnr/Zfp36l2tm1.1Tnr
Tg(CD2-icre)4Kio/0
Genetic
Background
involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CD2-icre)4Kio mutation (5 available)
Zfp36l1tm1.1Tnr mutation (0 available); any Zfp36l1 mutation (10 available)
Zfp36l2tm1.1Tnr mutation (0 available); any Zfp36l2 mutation (22 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• by 6 months of age, 90% of the mutant mice die or are humanely killed because of their ill health

neoplasm
• all mutant mice develop thymic tumors
• thymic tumors have high CD8 expression, with variable CD4 expression
• high expression of heat-stable antigen (CD24) but do not have surface expression of the TCR beta-chain (TCRbeta)
• most but not all tumors have intracellular expression of TCRbeta
• Notch1 mutation is present in a minority of tumors and affected mainly the heterodimerization domain (25%) rather than the PEST domain (8%)
• primary tumor cells cultured in vitro are Notch1 dependent and killed by Zfp36l1 re-expression
• development of T cell acute lymphoblastic leukemia
• circulating lymphoblasts in peripheral blood
• tumor cells in thymus, spleen, lymph node and bone marrow
• predominantly oligoclonal
• corresponding to the CD8+ immature single-positive (CD8iSP) and double-positive (DP) stages of thymic development

immune system
• perturbed thymopoiesis before tumor development
• thymic atrophy at 3 and 8 weeks of age
• gradual expansion of the CD8iSP population (CD8+CD4_CD24hi, membrane TCRbeta negative) in both proportion and absolute number by 13 weeks
• less progression from double-negative 2 (DN2) (CD44+CD25+) to DN3 (CD44_CD25+)
• decreased proportion of DN thymocytes with icTCRbeta expression
• only 30% of CD8iSP cells and 90% of DP cells have icTCRbeta expression
• thymic atrophy at 3 and 8 weeks of age
• total thymic cellularity is approximately 50% that of control mice
• all mutant mice develop thymic tumors
• thymic tumors have high CD8 expression, with variable CD4 expression
• high expression of heat-stable antigen (CD24) but do not have surface expression of the TCR beta-chain (TCRbeta)
• most but not all tumors have intracellular expression of TCRbeta
• Notch1 mutation is present in a minority of tumors and affected mainly the heterodimerization domain (25%) rather than the PEST domain (8%)
• primary tumor cells cultured in vitro are Notch1 dependent and killed by Zfp36l1 re-expression
• many mutant mice have splenomegaly
• many mutant mice have lymphadenopathy

cellular
• increased cellular proliferation by EdU staining in thymic populations from mice aged 5 and 10 weeks old

hematopoietic system
• perturbed thymopoiesis before tumor development
• thymic atrophy at 3 and 8 weeks of age
• gradual expansion of the CD8iSP population (CD8+CD4_CD24hi, membrane TCRbeta negative) in both proportion and absolute number by 13 weeks
• less progression from double-negative 2 (DN2) (CD44+CD25+) to DN3 (CD44_CD25+)
• decreased proportion of DN thymocytes with icTCRbeta expression
• only 30% of CD8iSP cells and 90% of DP cells have icTCRbeta expression
• thymic atrophy at 3 and 8 weeks of age
• total thymic cellularity is approximately 50% that of control mice
• all mutant mice develop thymic tumors
• thymic tumors have high CD8 expression, with variable CD4 expression
• high expression of heat-stable antigen (CD24) but do not have surface expression of the TCR beta-chain (TCRbeta)
• most but not all tumors have intracellular expression of TCRbeta
• Notch1 mutation is present in a minority of tumors and affected mainly the heterodimerization domain (25%) rather than the PEST domain (8%)
• primary tumor cells cultured in vitro are Notch1 dependent and killed by Zfp36l1 re-expression
• many mutant mice have splenomegaly

endocrine/exocrine glands
• perturbed thymopoiesis before tumor development
• thymic atrophy at 3 and 8 weeks of age
• gradual expansion of the CD8iSP population (CD8+CD4_CD24hi, membrane TCRbeta negative) in both proportion and absolute number by 13 weeks
• less progression from double-negative 2 (DN2) (CD44+CD25+) to DN3 (CD44_CD25+)
• decreased proportion of DN thymocytes with icTCRbeta expression
• only 30% of CD8iSP cells and 90% of DP cells have icTCRbeta expression
• thymic atrophy at 3 and 8 weeks of age
• total thymic cellularity is approximately 50% that of control mice
• all mutant mice develop thymic tumors
• thymic tumors have high CD8 expression, with variable CD4 expression
• high expression of heat-stable antigen (CD24) but do not have surface expression of the TCR beta-chain (TCRbeta)
• most but not all tumors have intracellular expression of TCRbeta
• Notch1 mutation is present in a minority of tumors and affected mainly the heterodimerization domain (25%) rather than the PEST domain (8%)
• primary tumor cells cultured in vitro are Notch1 dependent and killed by Zfp36l1 re-expression

growth/size/body
• many mutant mice have splenomegaly

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
acute lymphoblastic leukemia DOID:9952 OMIM:247640
OMIM:613065
J:162388


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory